Free Newsletter
ED drug gets nod as pulmonary ailment
File in the "new uses for approved drugs" drawer, in the erectile dysfunction med folder: United Therapeutics has persuaded the FDA to approve Eli Lilly's ED med tadalafil as a treatment for pulmonary arterial hypertension. Marketed under the name Adcirca, the drug will compete with treatments from Pfizer (Revatio), Actelion (Tracleer), and Gilead Sciences (Letairis). And it's not the only ED-type med on this particular shelf; Revatio contains the same primary ingredient as Pfizer's bestselling ED drug.
United licensed tadalafil from Lilly for this new indication, and now that it has an FDA approval in hand, plans to launch Adcirca in August. The licensing deal allows United to market the drug for PAH in the U.S. and Puerto Rico. It's expected to grab some market share from Pfizer's Revatio, analysts told Reuters.
ED drugs are being tested for all sorts of non-ED uses, usually as treatments for circulatory problems of one sort or another. Will this new indication be the last? Or not? What do you think?
- see United's release
- read the Bloomberg story
- see the article from Reuters
Related Articles:
Lilly's ED drug gets daily dose
Lilly promos run afoul of U.K. watchdog
ED drug scrips go online in U.K.
ED drugs slapped with new warning
United licenses drug indication to Lilly
Comments
By David D | Posted 6:03pm | May 28, 2009
PDE5s have many potential uses outside ED, especially in vascular disorders. The two that come to mind are Raynuad's Disease and Diabetic neuropathy. For raynaud's few disease options are available and the disease is estimated to impact 4-15% of the US population, primarily women.
Diabetic peripheral neuropathy is a progressive nerve disorder that occurs in more than 50% of diabetic patients in the US. Current therapies focus on the treating the pain caused by the neuropathy but not the underlying disease.
By <A href="http://www.pharmacyonline.com/" title="pharmacy onl | Posted 10:37am | October 6, 2009
hi
licensing deal allows United to market the drug for PAH in the U.S. and Puerto Rico. It's expected to grab some market share from Pfizer's Revatio, analysts told Reuters.
Read more: http://www.fiercepharma.com/story/ed-drug-gets-nod-pulmonary-ailment
By <a href="http://www.pharmacy/">pharmacy</a> | Posted 10:40am | October 6, 2009
hi great PDE5s have many potential uses outside ED, especially in vascular disorders. The two that come to mind are Raynuad's Disease and Diabetic neuropathy. For raynaud's few disease options are available and the disease is estimated to impact 4-15% of the US population, primarily women.
Diabetic peripheral neuropathy is a progressive nerve disorder that occurs in more than 50% of diabetic patients in the US. Current therapies focus on the treating the pain caused by the neuropathy but not the underlying disease.
Read more: http://www.fiercepharma.com/story/ed-drug-gets-nod-pulmonary-ailment/2009-05-26#comment-2045#ixzz0TAQT5kQj
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: